Customers may be starting to shop for over-the-counter drugs in the same way they shop for groceries—with a keener eye for cost and content. This could be painful for consumer-health companies who thought they were insulated from changing tastes. Pharmaceutical giant Pfizer said last week that it was “reviewing strategic alternatives” for its non-prescription business, which makes ibuprofen brand Advil and Centrum multivitamin packs. German peer Merck (which is separate from the U.S. Merck) made a similar announcement in September.
Source: Wall Street Journal October 16, 2017 10:30 UTC